查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1835283

人体肝臟模型市场（按模型类型、细胞来源、应用和最终用户）—2025-2032 年全球预测

Human Liver Model Market by Model Type, Cell Source, Application, End Users - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，人体肝臟模型市场将成长 30.5 亿美元，复合年增长率为 8.75%。

主要市场统计数据
基准年2024年 15.5亿美元
预计2025年 16.8亿美元
预测年份：2032年 30.5亿美元
复合年增长率（%） 8.75%

技术整合和实践检验的整体情况将决定人类肝臟模型未来的效用和操作应用

人体肝臟模型的演变代表着生物学、工程学和计算科学的融合，重塑了学术界和产业界以肝臟为重点的研发方式。支架设计、微生理系统、干细胞分化方案和多组体学读数的进步提高了生理相关性，并使药物代谢、肝毒性和疾病建模的研究更具预测性。这些技术改进正被应用于从早期标靶检验到后期转化研究的各种工作流程，迫使研究机构重新思考实验设计和资源分配。

重要的是，疫情期间远端协作和数位数位资料整合的加速，扩大了对In Silico方法的需求，以补充湿实验室模型，从而创建将二维平台、三维结构与计算模拟相结合的混合工作流程。因此，相关人员更加重视模型的可重复性、标准化以及与高内涵读数的兼容性。因此，优先考虑跨学科验证和可扩展製造实践的组织将更有能力将模型改进转化为可重复且符合法规要求的结果。

展望未来，人体肝臟模型的常规应用正从概念验证转向实际操作和资格确认阶段。这项转变需要在品管、检测方法协调以及临床和临床前终点的透明基准测试方面进行策略性投资，从而为其在药物安全、疾病研究和教育领域的更广泛效用奠定基础。

突破性工程、品质主导的商业化和协作标准化如何重塑先进人体肝臟模型的接受度和用例

由于科学突破和相关人员期望的转变，人类肝臟模型的格局正在发生重大变化。细胞获取、微流体整合和资料读取方面的进步，已将微生理系统和肝臟类器官从单一的研究工具转变为为药物研发和安全评估提供决策依据的平台。这种转变正在促进跨学科伙伴关係，将组织工程与计算预测相结合，从而产生更丰富的多模态资料集，以支援机制研究。

同时，最终用户对可重复性和通量的要求也越来越高，这推动了製造、自动化和品管领域的创新。受託研究机构和生物技术公司越来越多地提供承包模型解决方案，降低了需要稳健、可扩展方案的製药项目和学术实验室的准入门槛。同时，学术团体继续专注于疾病特异性建模，特别是代谢性和纤维化肝病，从而拓展了肝臟模型至关重要的生物学应用范围。

这些发展也推动了跨部门合作的新形式，包括与监管机构进行试点资格确认研究、建立竞争前联盟以製定基准化分析标准，以及官民合作关係以加速转化进程。总而言之，这些转变正在重新定义人们对经过验证、可立即用于决策的肝臟模型的期望。

分析 2025 年关税趋势的变化如何推动模型开发商的策略供应链多样化、本地化和采购弹性

2025年的关税政策和贸易动态为在国际范围内采购材料、设备和模型系统的组织带来了新的策略考量。为了应对这些关税带来的成本压力，许多供应商和最终用户正在重新评估其供应链布局和筹资策略，以保持其科学研究营运的连续性。这加速了人们对关键零件（例如微流体晶片、细胞外基质材料以及支援可重复肝臟模型生成的标准化耗材）的本地製造能力的兴趣。

因此，相关人员优先考虑供应链的韧性，透过提高透明度并透过供应商多元化和更紧密的供应商关係提供应急计画。同时，各组织正在评估垂直整合某些功能（例如细胞衍生、品管和检测自动化）与依赖外部服务提供者的成本效益。这些策略倡议正在与保持地理集中度以及维持对专业知识和创新中心的存取权的需求之间取得平衡。

因此，关税环境促使人们更广泛地重新思考采购、製造规模和伙伴关係模式，凸显了适应性筹资策略、本地製造投资以及减轻地缘政治和监管风险的合约机制的重要性。

细分情报揭示了模型类型、细胞来源、应用重点和最终用户优先级如何决定采用路径和商业化策略

细緻的细分视角揭示了不同模型类型、细胞来源、应用程式和最终用户类别中不同的应用驱动因素和业务需求。模型类型涵盖传统的二维模型、新兴的三维模型、体外构建体、In Silico模拟和肝臟器官，每种模型在生理相关性、扩充性和整合复杂性之间都有其独特的权衡。优先考虑高筛检的架构通常会保留二维平台以实现成本效益和简便性，而专注于转化保真度的项目则越来越多地投资于三维构建体和类器官，以捕捉多细胞结构和功能终点。

从永生化细胞株和原代人类肝细胞到干细胞衍生模型，细胞来源的选择会影响实验设计和后续结果解读。原代细胞具有与临床相似的表型，但在供应和变异性方面存在挑战。另一方面，干细胞衍生方法为疾病建模提供了扩充性和灵活性。永生化细胞係对于机制阐明和检测方法开发仍然效用，尤其是与基因编辑和标准化读数相结合时。在药物研发中，平衡通量和预测值至关重要，而生理学和毒理学研究等教育目的则优先考虑可重复性和成本效益，以支持课程和培训目标。

生物技术和製药公司专注于转化验证及其与前临床开发平臺的整合，企业合约研究组织专注于服务扩充性和法规合规性，研究实验室则专注于实验灵活性和新颖的假设检验。了解模型类型、细胞来源、应用和最终用户优先顺序之间的相互关係，对于设计满足不同相关人员需求的商业化方法、伙伴关係和检验研究至关重要。

美洲、欧洲、中东和非洲以及亚太地区的战略对比和能力将决定招聘轨迹和伙伴关係机会

美洲、欧洲、中东和非洲以及亚太地区的区域动态将对应用程式时程、商业化策略和伙伴关係模式产生重大影响。美洲地区拥有强大的转化生态系统，且接近性主要製药中心，这有利于早期采用高保真度3D系统和类器官，并专注于将模型整合到安全性和代谢工作流程中。该地区的资金筹措格局和创投活动也青睐那些能够证明符合监管环境并具备可扩展製造能力的新兴企业。

欧洲、中东和非洲 欧洲、中东和非洲展现出多元化的学术成就、监管参与和产业合作，促进了严格的检验工作和竞争前联盟的形成。该地区通常在为复杂的组织模式建立跨学科标准和伦理框架方面发挥主导作用，从而开闢了获得资格的途径。相较之下，亚太地区以快速的生产规模扩大、具有成本竞争力的服务交付以及对生物技术基础设施的策略性公共投资而闻名，使其成为本地生产、大规模合约服务和临床转化倡议的关键地区。

针对每个地区制定量身定制的策略至关重要，要认识到监管互动、资金筹措机制和製造能力的差异。合作伙伴和投资者需要製定产业计画，充分利用当地优势，利用当地人才库和基础设施，同时满足全球认证和品质要求。

对竞争格局、伙伴关係模式和验证主导的差异化策略的考虑将决定人类肝臟模型领域的潜在领导地位

现有企业、专业新兴企业和服务供应商之间的竞争动态，由平台工程、细胞采购、检测方法开发和监管参与的互补优势所塑造。领先的学术衍生公司和生物技术公司凭藉专有的差异化方案、微加工专业知识和整合分析工具链脱颖而出，为最终用户提供可靠的测量结果。同时，合约委外研发机构和平台提供者越来越多地建立策略伙伴关係，提供满足端到端需求的配套服务，从模型资格确认和检测方法验证到符合GLP（良好实验室规范）的资料收集。

平台开发商和製药团队之间的合作日益频繁，他们透过签订共同开发契约和中试资格确认研究来降低药物开发平臺的整合风险。此外，人们对授权协议和策略投资的兴趣日益浓厚，以加速规模化和市场准入，尤其是在共享能够证明转化一致性的验证资料集方面。对于寻求竞争的公司而言，成功取决于清晰的价值主张、检验的效能声明以及可证明的营运扩充性，以支援多样化的客户工作流程。

投资者和企业开发团队应密切追踪伙伴关係、技术转移协议和平台互通性倡议，因为这些活动通常预示着更广泛的商业性应用，并基于数据生态系统和检验端点设置差异化障碍。

为领导者提供实际的优先行动，以标准化检验、扩大生产规模、建立策略合作伙伴关係，并使商业模式与最终用户需求保持一致

产业领导者应采取积极主动的方法，在科学严谨性、营运扩充性和商业性诚信之间取得平衡。首先，优先考虑标准化验证框架，该框架将模型输出映射到临床相关的生物标记物，并为整合到药物发现和安全工作流程中提供清晰的决策闸。同时，投资扩充性的生产和品质体系，以减少合作伙伴和客户的差异性，并缩短资格确认时间。儘早与监管相关人员沟通并参与跨部门基准化分析倡议，可以加快产品被接受的速度并降低转换风险。

其次，寻求能够补充您内部能力的策略伙伴关係。例如，与计算生物学团队合作进行In Silico集成，与细胞疗法创新者合作以增强细胞采购，并与合约研究公司合作提供服务以扩大您的业务范围。第三，透过提供灵活的商业模式（例如基于订阅的存取、试点资格套餐以及针对学术计画的教育许可），使您的市场进入策略与最终用户需求保持一致。最后，透过考虑区域製造、多供应商协议和库存对冲来保持灵活的筹资策略，以避免地缘政治和关税压力并保持业务连续性。

透过应对这些挑战，公司可以加快模型认证，扩大市场进入，并基于检验的性能和以客户为中心的交付建立稳固的地位。

采用严格的混合方法，结合主要专家访谈、技术文献综合和迭代检验，确保了可操作且可靠的研究结果

本执行摘要所依据的研究结合了与领域专家的结构化一手访谈，以及对同行评审文献、技术白皮书、监管指南和公司披露资讯的二次综合。关键的定性资讯包括与平台开发者、细胞采购专家、製药公司和合约研发的最终用户，以及在疾病相关环境中应用模型的转化科学家的访谈。这些对话提供了关于营运挑战、检验重点以及商业性化应用驱动因素的详细见解。

我们的二次分析系统地回顾了组织工程、干细胞分化方案、微流体和计算建模方面的方法学进展，并结合近期临床前和转化研究的调查，对模型性能进行了基准测试。我们也透过专家检验会议反覆完善研究结果，以确保技术准确性和实务相关性。我们也考虑了伦理考量、生产限制以及与监管机构的沟通，以提供平衡的观点来支持策略决策。

这种混合方法确保结论既反映当前的科学进步状况，也反映开发人员、最终用户和投资者面临的营运现实。

营运准备、检验严谨性和策略一致性将决定谁将主导将模型进步转化为实际研究和商业性价值。

总而言之，在技术融合、细胞采购改进以及对可重复性和监管相关性更高期望的推动下，人类肝臟模型生态系统正从探索性创新走向成熟，迈向营运就绪。投资于稳健验证、可扩展生产和策略伙伴关係关係的相关人员将最有能力将模型效能转化为实际的研究和商业性成果。同时，地缘政治和关税因素正在重塑供应链策略，凸显了对在地化能力和多元化采购的需求。

这意味着要优先考虑湿实验室和In Silico方法之间的互通性，积极与监管机构和联盟合作制定验收标准，并设计符合最终用户工作流程的商业产品。透过这样做，组织不仅可以提高实验的可预测性，还可以在药物研发、毒理学教育和疾病建模等领域开闢新的应用，从而提昇科学价值和商业性价值。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 3D生物列印人体肝组织在高通量药物肝毒性筛检的应用日益广泛
  • 将微流体肝臟晶片平台与多器官系统结合，实现全面的药物动力学建模
  • iPSC 衍生的肝类器官的兴起使得创建患者特异性疾病模型和个人化治疗发现成为可能
  • 生物技术公司与学术中心建立策略伙伴关係关係，扩大标准化人体肝臟模型生产
  • 监管参与和标准化努力，推动体外人体肝臟模型在医药品认证过程中的接受

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 人体肝臟模型市场（依模型类型）

  • 2D模型
  • 3D模型
  • 体外模型
  • In Silico模型
  • 肝臟类器官

9. 人体肝臟模型市场（依细胞来源）

  • 永生化肝细胞株
  • 原代人类肝细胞
  • 干细胞衍生模型

第十章人体肝臟模型市场（依应用）

  • 药物研发
  • 教育
    • 生理研究
    • 毒理学研究

第 11 章人体肝臟模型市场（依最终用户划分）

  • 生技公司
  • 合约研究组织
  • 製药公司
  • 实验室

12. 人体肝臟模型市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章人体肝臟模型市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国人体肝臟模型市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Ascendance Bio
    • BioIVT LLC
    • Cellink Global by BICO Group AB
    • CN Bio Innovations Ltd.
    • Corning Incorporated
    • Cyfuse Biomedical KK
    • EISCO Scientific LLC
    • Emulate Inc.
    • Hurel Corporation
    • InSphero AG
    • Kirkstall Ltd
    • MIMETAS BV
    • NeurOmics, Inc.
    • Organovo Holdings Inc.
    • Pandorum Technologies Private Limited
    • PhoenixBio Co., Ltd.
    • STEMCELL Technologies Inc.
Product Code: MRR-43127F7278DC

The Human Liver Model Market is projected to grow by USD 3.05 billion at a CAGR of 8.75% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.55 billion
Estimated Year [2025] USD 1.68 billion
Forecast Year [2032] USD 3.05 billion
CAGR (%) 8.75%

A panoramic overview of technological integration and practical validation shaping the future utility and operational adoption of human liver models

The evolution of human liver models represents a convergence of biology, engineering, and computational sciences that is reshaping how industry and academia approach liver-focused research and development. Advances in scaffold design, microphysiological systems, stem cell differentiation protocols, and multi-omics readouts have collectively improved physiological relevance, enabling more predictive interrogation of drug metabolism, hepatotoxicity, and disease modeling. These technological improvements are being adopted across diverse workflows, from early-stage target validation to later-stage translational research, which is prompting institutions to reassess experimental design and resource allocation.

Importantly, the pandemic-era acceleration of remote collaboration and digital data integration has amplified demand for in silico approaches that complement wet-lab models, thereby creating hybrid workflows that combine 2D platforms and 3D constructs with computational simulations. As a result, stakeholders are placing greater emphasis on model reproducibility, standardization, and compatibility with high-content readouts. Consequently, organizations that prioritize cross-disciplinary validation and scalable manufacturing practices will be better positioned to translate model improvements into reproducible, regulatory-relevant outcomes.

Looking ahead, the narrative is shifting from proof-of-concept demonstrations to operationalization and qualification of human liver models for routine use. This transition demands strategic investments in quality management, assay harmonization, and transparent benchmarking against clinical and preclinical endpoints, establishing a foundation for broader utility in drug safety, disease research, and education.

How breakthrough engineering, quality-driven commercialization, and collaborative standards are reconfiguring acceptance and use cases for advanced human liver models

The landscape for human liver models is undergoing transformative shifts driven by a combination of scientific breakthroughs and changing stakeholder expectations. Microphysiological systems and liver organoids are moving from niche research tools to platforms that can inform decision-making across drug discovery and safety assessment, driven by improvements in cellular sourcing, microfluidic integration, and readout sophistication. This shift is encouraging multidisciplinary partnerships that marry tissue engineering with computational prediction, thereby enabling richer, multi-modal datasets that support mechanistic insights.

Simultaneously, end users are demanding higher standards for reproducibility and throughput, prompting innovations in manufacturing, automation, and quality control. Contract research organizations and biotech companies are increasingly offering turnkey model solutions, lowering barriers to adoption for pharmaceutical programs and academic labs that need robust, scalable options. In parallel, academic groups continue to push the envelope on disease-specific modeling, particularly for metabolic and fibrotic liver conditions, which is expanding the biological contexts in which liver models are considered indispensable.

These developments are also prompting new modalities of collaboration across sectors, including pilot qualification studies with regulators, pre-competitive consortia to define benchmarking standards, and private-public partnerships that accelerate translational pathways. Collectively, these shifts are redefining expectations for what constitutes a validated, decision-grade liver model.

Analyzing how evolving tariff dynamics in 2025 are prompting strategic supply chain diversification, localized manufacturing, and procurement resilience for model developers

Tariff policies and trade dynamics in 2025 have introduced a new set of strategic considerations for organizations that source materials, equipment, and model systems internationally. In response to these tariff-induced cost pressures, many suppliers and end users are reevaluating supply chain footprints and sourcing strategies to maintain continuity of scientific operations. This has accelerated interest in regional manufacturing capabilities for critical components such as microfluidic chips, extracellular matrix materials, and standardized consumables that support reproducible liver model production.

As a result, stakeholders are increasingly prioritizing supply chain resilience through diversification of vendors and closer supplier relationships that offer greater transparency and contingency planning. At the same time, organizations are assessing the cost-benefit of vertically integrating certain capabilities-such as cell derivation, quality control, and assay automation-versus relying on external service providers. These strategic moves are being balanced with the need to preserve access to specialized expertise and innovation hubs that remain geographically concentrated.

Consequently, the tariff environment has catalyzed a broader rethinking of procurement, manufacturing scale, and partnership models, underlining the importance of adaptive sourcing strategies, localized production investments, and contractual mechanisms that mitigate geopolitical and regulatory risk.

Segment-level intelligence revealing how model type, cell source, application focus, and end-user priorities determine adoption pathways and commercialization strategies

A nuanced view of segmentation reveals differentiated adoption drivers and operational imperatives across model type, cell source, application, and end-user categories. Model types span traditional 2D models and emerging 3D models, Ex Vivo constructs, In Silico simulations, and Liver Organoids, each offering unique trade-offs between physiological relevance, scalability, and integration complexity. Organizations that prioritize high-throughput screening often retain 2D platforms for their cost-effectiveness and simplicity, while programs focused on translational fidelity are increasingly investing in 3D constructs and organoids to capture multicellular architecture and functional metrics.

Cell source decisions-ranging from Immortalized Liver Cell Lines and Primary Human Hepatocytes to Stem Cell-Derived Models-inform both experimental design and downstream interpretation. Primary cells offer clinically proximal phenotypes but present supply and variability challenges, whereas stem cell-derived approaches provide scalability and disease modeling flexibility. Immortalized lines maintain utility for mechanistic probing and assay development, especially when combined with genetic editing and standardized readouts. These choices cascade into application-specific strategies: drug discovery initiatives balance throughput and predictive value, while educational uses, including physiological and toxicology studies, emphasize reproducibility and cost-efficiency to support curriculum and training objectives.

End-user profiles further shape technology adoption pathways, with Biotech Companies and Pharmaceutical Companies focusing on translational validation and integration with preclinical pipelines, Contract Research Organizations centering on service scalability and regulatory alignment, and Research Laboratories prioritizing experimental flexibility and novel hypothesis testing. Understanding how model type, cell source, application, and end-user priorities interrelate is critical for designing commercialization approaches, partnerships, and validation studies that meet diverse stakeholder needs.

Regional strategic contrasts and capabilities across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine adoption trajectories and partnership opportunities

Regional dynamics materially influence adoption timelines, commercialization strategies, and partnership models across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, strong translational ecosystems and proximity to major pharmaceutical hubs support early adoption of higher-fidelity 3D systems and organoids, with an emphasis on integrating models into safety and metabolism workflows. Funding landscapes and venture activity in this region also favor startups that can demonstrate regulatory alignment and scalable manufacturing.

Europe, Middle East & Africa exhibit a diverse mosaic of academic excellence, regulatory engagement, and industrial collaboration that fosters rigorous validation efforts and pre-competitive consortia. This region often leads in establishing interdisciplinary standards and ethical frameworks for complex tissue models, which in turn informs qualification pathways. In contrast, the Asia-Pacific region is notable for rapid manufacturing scale-up, cost-competitive service provision, and strategic public investment in biotechnology infrastructure, making it a pivotal zone for localized production, large-scale contract services, and clinical translation initiatives.

A regionally attuned strategy that recognizes differences in regulatory dialogue, funding mechanisms, and manufacturing capacities will be essential. Partners and investors should align operational plans with regional strengths, leveraging local talent pools and infrastructure while ensuring harmonization with global validation and quality expectations.

Insight into competitive positioning, partnership models, and validation-driven differentiation strategies that dictate leadership potential in the human liver model landscape

Competitive dynamics among established firms, specialized startups, and service providers are shaped by complementary strengths in platform engineering, cell sourcing, assay development, and regulatory engagement. Leading academic spinouts and biotech companies often differentiate through proprietary differentiation protocols, microfabrication expertise, and integrated analytical toolchains that provide end users with higher-confidence readouts. At the same time, contract research organizations and platform providers are increasingly forming strategic partnerships to offer bundled services that address end-to-end needs-from model qualification and assay validation to GLP-compatible data capture.

Collaboration between platform developers and pharmaceutical teams is becoming more frequent, with co-development agreements and pilot qualification studies used to de-risk integration into drug development pipelines. Additionally, there is growing interest in licensing arrangements and strategic investments that accelerate scale-up and market reach, especially when combined with shared validation datasets that demonstrate translational concordance. For companies seeking to compete, success depends on clear value articulation, validated performance claims, and demonstrable operational scalability to support diverse customer workflows.

Investors and corporate development teams should track partnerships, technology transfer agreements, and platform interoperability initiatives closely, as these activities often presage broader commercial uptake and create differentiation barriers based on data ecosystems and validated endpoints.

Practical, prioritized actions for leaders to standardize validation, scale manufacturing, form strategic alliances, and align commercial models with end-user needs

Industry leaders should adopt a proactive approach that balances scientific rigor, operational scalability, and commercial alignment. First, prioritize standardized validation frameworks that map model outputs to clinically relevant biomarkers, enabling clearer decision gates for integration into drug discovery and safety workflows. Concurrently, invest in scalable manufacturing and quality systems to reduce variability and shorten qualification timelines for partners and customers. Early engagement with regulatory stakeholders and participation in cross-sector benchmarking initiatives will accelerate acceptance and reduce translational risk.

Second, pursue strategic partnerships that complement internal capabilities-such as collaborations with computational biology groups for in silico integration, alliances with cell therapy innovators for enhanced cell sourcing, and service partnerships with contract research providers to expand reach. Third, tailor go-to-market strategies to end-user needs by offering flexible commercial models that include subscription-based access, pilot qualification packages, and educational licensing for academic programs. Finally, maintain an adaptive sourcing strategy to navigate geopolitical and tariff pressures by exploring regional manufacturing, multi-supplier agreements, and inventory hedging that preserve operational continuity.

By executing on these fronts, organizations can accelerate model qualification, broaden market access, and establish defensible positions grounded in validated performance and customer-centric delivery.

A rigorous mixed-methods approach combining primary expert interviews, technical literature synthesis, and iterative validation to ensure actionable and credible findings

The research underpinning this executive summary combined structured primary engagement with subject-matter experts and secondary synthesis of peer-reviewed literature, technical whitepapers, regulatory guidance, and company disclosures. Key qualitative inputs included interviews with platform developers, cell sourcing specialists, end users in pharmaceutical and contract research settings, and translational scientists who apply models in disease-relevant contexts. These conversations provided granular insights into operational challenges, validation priorities, and commercial adoption drivers.

Secondary analysis involved systematic review of methodological advancements in tissue engineering, stem cell differentiation protocols, microfluidics, and computational modeling, supplemented by examination of recent preclinical and translational studies that benchmark model performance. Data triangulation was used to cross-validate thematic findings across sources, and findings were iteratively refined through expert validation sessions to ensure technical accuracy and practical relevance. Ethical considerations, manufacturing constraints, and regulatory dialogue were also incorporated to present a balanced view that supports strategic decision-making.

This mixed-methods approach ensures that conclusions reflect both the current state of scientific advancement and the operational realities facing developers, end users, and investors.

Key takeaways emphasizing operational readiness, validation rigor, and strategic alignment that will determine who leads in translating model advancements into practical research and commercial value

In conclusion, the human liver model ecosystem is maturing from exploratory innovation toward operational readiness, driven by technological convergence, improved cellular sourcing, and higher expectations for reproducibility and regulatory relevance. Stakeholders who invest in robust validation, scalable manufacturing, and strategic partnerships will be best positioned to translate model performance into tangible research and commercial outcomes. At the same time, geopolitical and tariff considerations are reshaping supply chain strategies, highlighting the need for localized capabilities and diversified sourcing.

The implications for industry participants are clear: prioritize interoperability between wet-lab and in silico approaches, engage proactively with regulators and consortia to define acceptance criteria, and design commercial offerings that map to end-user workflows. By doing so, organizations can not only improve experimental predictability but also unlock new applications in drug discovery, toxicology education, and disease modeling that together advance both science and commercial value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of 3D bioprinted human liver tissues for high throughput drug hepatotoxicity screening
  • 5.2. Integration of microfluidic liver on chip platforms with multi organ systems for holistic pharmacokinetic modeling
  • 5.3. Rise of iPSC derived liver organoids enabling patient specific disease modeling and personalized therapeutic discovery
  • 5.4. Strategic partnerships between biotech firms and academic centers to scale standardized human liver model production
  • 5.5. Regulatory engagement and standardization efforts for acceptance of in vitro human liver models in drug approval process

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Liver Model Market, by Model Type

  • 8.1. 2D Models
  • 8.2. 3D Models
  • 8.3. Ex Vivo Models
  • 8.4. In Silico Models
  • 8.5. Liver Organoids

9. Human Liver Model Market, by Cell Source

  • 9.1. Immortalized Liver Cell Lines
  • 9.2. Primary Human Hepatocytes
  • 9.3. Stem Cell-Derived Models

10. Human Liver Model Market, by Application

  • 10.1. Drug Discovery
  • 10.2. Education
    • 10.2.1. Physiological Studies
    • 10.2.2. Toxicology Studies

11. Human Liver Model Market, by End Users

  • 11.1. Biotech Companies
  • 11.2. Contract Research Organizations
  • 11.3. Pharmaceutical Companies
  • 11.4. Research Laboratories

12. Human Liver Model Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Human Liver Model Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Human Liver Model Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Ascendance Bio
    • 15.3.2. BioIVT LLC
    • 15.3.3. Cellink Global by BICO Group AB
    • 15.3.4. CN Bio Innovations Ltd.
    • 15.3.5. Corning Incorporated
    • 15.3.6. Cyfuse Biomedical K.K.
    • 15.3.7. EISCO Scientific LLC
    • 15.3.8. Emulate Inc.
    • 15.3.9. Hurel Corporation
    • 15.3.10. InSphero AG
    • 15.3.11. Kirkstall Ltd
    • 15.3.12. MIMETAS B.V.
    • 15.3.13. NeurOmics, Inc.
    • 15.3.14. Organovo Holdings Inc.
    • 15.3.15. Pandorum Technologies Private Limited
    • 15.3.16. PhoenixBio Co., Ltd.
    • 15.3.17. STEMCELL Technologies Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN LIVER MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HUMAN LIVER MODEL MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HUMAN LIVER MODEL MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HUMAN LIVER MODEL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HUMAN LIVER MODEL MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN LIVER MODEL MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 2D MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 2D MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 2D MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 2D MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 2D MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 2D MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 3D MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 3D MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 3D MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 3D MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 3D MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY 3D MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EX VIVO MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IN SILICO MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IN SILICO MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IN SILICO MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IN SILICO MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IN SILICO MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IN SILICO MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY LIVER ORGANOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY LIVER ORGANOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY LIVER ORGANOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY LIVER ORGANOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY LIVER ORGANOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY LIVER ORGANOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IMMORTALIZED LIVER CELL LINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IMMORTALIZED LIVER CELL LINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IMMORTALIZED LIVER CELL LINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IMMORTALIZED LIVER CELL LINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IMMORTALIZED LIVER CELL LINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY IMMORTALIZED LIVER CELL LINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PRIMARY HUMAN HEPATOCYTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PRIMARY HUMAN HEPATOCYTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PRIMARY HUMAN HEPATOCYTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PRIMARY HUMAN HEPATOCYTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PRIMARY HUMAN HEPATOCYTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PRIMARY HUMAN HEPATOCYTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY STEM CELL-DERIVED MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY STEM CELL-DERIVED MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY STEM CELL-DERIVED MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY STEM CELL-DERIVED MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY STEM CELL-DERIVED MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY STEM CELL-DERIVED MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHYSIOLOGICAL STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHYSIOLOGICAL STUDIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHYSIOLOGICAL STUDIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHYSIOLOGICAL STUDIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHYSIOLOGICAL STUDIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHYSIOLOGICAL STUDIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY TOXICOLOGY STUDIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY TOXICOLOGY STUDIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY TOXICOLOGY STUDIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY TOXICOLOGY STUDIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 178. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 185. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 190. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 191. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 192. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 216. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 217. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 218. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 219. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 220. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 221. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 222. ASEAN HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 223. GCC HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GCC HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GCC HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. GCC HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. GCC HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 228. GCC HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 229. GCC HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. GCC HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. GCC HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 232. GCC HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 233. GCC HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 234. GCC HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPEAN UNION HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 247. BRICS HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. BRICS HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. BRICS HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. BRICS HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. BRICS HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 252. BRICS HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 253. BRICS HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 254. BRICS HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 255. BRICS HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 256. BRICS HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 257. BRICS HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 258. BRICS HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 259. G7 HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. G7 HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. G7 HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. G7 HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. G7 HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 264. G7 HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 265. G7 HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. G7 HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. G7 HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 268. G7 HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 269. G7 HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 270. G7 HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 271. NATO HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. NATO HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. NATO HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. NATO HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. NATO HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 276. NATO HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 277. NATO HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 278. NATO HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 279. NATO HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 280. NATO HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 281. NATO HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 282. NATO HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL HUMAN LIVER MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 289. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 291. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 293. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED STATES HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 295. CANADA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. CANADA HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. CANADA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 298. CANADA HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 299. CANADA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 300. CANADA HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 301. CANADA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 302. CANADA HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 303. CANADA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 304. CANADA HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 305. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 308. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 309. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 310. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 311. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 312. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 313. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 314. MEXICO HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 315. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 318. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 319. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 320. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 321. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 322. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 323. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 324. BRAZIL HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 325. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 327. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 329. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 331. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 332. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 333. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED KINGDOM HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 335. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 338. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 339. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 340. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 341. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2018-2024 (USD MILLION)
  • TABLE 342. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY EDUCATION, 2025-2032 (USD MILLION)
  • TABLE 343. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 344. GERMANY HUMAN LIVER MODEL MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 345. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. FRANCE HUMAN LIVER MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 347. FRANCE HUMAN LIVER